TrialNature medicine2024

Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.

Mark Yarchoan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.